CMND - Clearmind Medicine Inc. News

Sectors

CMND

Clearmind Medicine Inc.

1.94

2 x 1.51

2 x 2.30

bid

ask

0.18

9.92%

2 @ 07:02 PM

1.92 -0.02 (0.85%)

Ytd	-89.28%
1y	-99.54%

1.81

day range

2.10

1.43

52 week range

524.00

Open	1.82	Prev Close	1.76	Low	1.81	High	2.10	Mkt Cap	2.88M
Vol	710.15K	Avg Vol	1.17M	EPS	-175.92	P/E	N/A	Forward P/E	N/A
Beta	-1.51	Short Ratio	1.88	Inst. Own	16.02%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	N/A	50-d Avg	1.95	200-d Avg	16.90	1yr Est	0.00

CMND News

benzinga.com

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Com

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its sub

benzinga.com

Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-h

globenewswire.com

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Su

U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands

thenewswire.com

NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Am

U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands i

benzinga.com

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine

benzinga.com

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C fo

globenewswire.com

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva

globenewswire.com

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting

Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY

globenewswire.com

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva

globenewswire.com

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solu

Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm

benzinga.com

Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clin

Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candid

globenewswire.com

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Thr

Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

benzinga.com

Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clin

All 24 participants across cohorts 1 through 4 have successfully completed treatment according to th

globenewswire.com

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Compan

benzinga.com

Clearmind Medicine Files Hong Kong Patent Application For Innovative Psychedelic Compounds For Treat

The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement w

globenewswire.com

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Co

Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ("Clearmind") (Nasdaq:

globenewswire.com

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Hea

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

benzinga.com

Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demon

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potent

globenewswire.com

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-

Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

benzinga.com

Clearmind Medicine Announces CMND‑100, Current Phase I/IIa Trial Demonstrates Impression To Treat Al

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

globenewswire.com

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with

benzinga.com

Clearmind Medicine Files Response To U.S. Department Of Health And Human Services Request For Inform

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hall

globenewswire.com

Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as

Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

benzinga.com

Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Trea

The program is evaluating intranasal delivery of MEAI as a potential additional route of administrat

globenewswire.com

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route

Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

benzinga.com

Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

globenewswire.com

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent S

Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearm

benzinga.com

Clearmind Medicine Completes Treatment For All Participants In Part A Of Ongoing Phase I/II Clinical

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

UPDATE: Clearmind Medicine Secures U.S. Patent Covering MEAI-Based Compositions And Methods For Regu

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

Clearmind Medicine Completes Dosing Of All 24 Participants In Groups 1 To 4 Of Part A Of Its Phase I

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Clearmind Medicine To Host June 10 Webinar On The Latest Clinical Data From Its Phase I/IIa Trial Ev

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

Clearmind Medicine Files Japanese Patent Application For Its Proprietary Compositions Comprising 5-M

This advancement strengthens Clearmind's robust intellectual property portfolio, which already

benzinga.com

Clearmind Medicine Announces Johns Hopkins Approval For CMND-100 Phase 1/2 Clinical Trial

The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolera

benzinga.com

Gold Falls 1%; Amer Sports Earnings Top Views

US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&

benzinga.com

Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings

US stocks fall, Dow Jones down 0.34% & NASDAQ down 0.41% in morning trading. Home Depot reports

benzinga.com

Clearmind Medicine Inks Research Agreement With Yissum Research Development To Evaluate Metabolic Ef

Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-st

benzinga.com

Clearmind Medicine Announces Dosing Of Two Additional Patients In Fourth Group Of Its Phase I/IIa Cl

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

Clearmind Medicine Shares New CMND-100 Clinical Trial Data Ahead Of June Investor Webinar

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

benzinga.com

Clearmind Medicine Files European Patent Application For Innovative Psychedelic Compounds Targeting

The European patent application forms part of the Company's exclusive worldwide licensing agreem

benzinga.com

Clearmind Medicine Evaluates Lead Candidate, CMND-100 (MEAI), For Eligibility For FDA's Breakthrough

Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for elig

benzinga.com

Why Is Clearmind Medicine Stock Sliding On Wednesday?

Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. R

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session